Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement (NCT05727176)
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements
🩺 Plain-English Summary (8th-Grade Level)
This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.
Who can join: Review the eligibility criteria below.
Location: University of California San Diego UCSD - Moores Cancer Center — La Jolla, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (65 Sites)
Showing the first 25 of 65 sites.
- University of California San Diego UCSD - Moores Cancer Center — La Jolla, California
- Tampa General Hospital Cancer Institute — Tampa, Florida
- Henry Ford Health System — Detroit, Michigan
- Gabrail Cancer Center Research — Canton, Ohio
- Texas Oncology — Abilene, Texas
- The Liver Institute at Methodist Dallas Medical Center — Dallas, Texas
- Texas Oncology Methodist DFW — Dallas, Texas
- Texas Onc Methodist (Charlton) — Dallas, Texas
- Texas Oncology - Northeast — Denton, Texas
- Center for Oncology and Blood Disorders — Houston, Texas
- Hospital Britanico — Buenos Aires,
- CEMIC — CABA,
- Sanatorio de la Mujer — Rosario,
- St Vincent's Hospital Sydney - The Kinghorn Cancer Centre — Sydney, New South Wales
- Alfred Health, Medical Oncology Unit, Second floor William Buckland Radiotherapy Center — Melbourne, Victoria
- St John of God Subiaco Hospital — Subiaco, Western Australia
- Instituto do Cancer do Estado de Sao Paulo — Cerqueira César,
- IOP - Instituto de Oncologia do Parana — Curitiba,
- Hospital Erasto Gaertner — Curitiba,
- Hospital de Base de Sao Jose do Rio Preto — São José do Rio Preto,
- Fundacao Antonio Prudente - A.C.Camargo Cancer Center — São Paulo,
- Sunnybrook Health Sciences Center — Toronto, Ohio
- Grand River Hospital - Grand River Regional Cancer Centre (GRRCC) — Kitchener, OH
- University of Toronto — Toronto, OH
- McGill University Health Center — Montreal, Quebec
📞 Contact the Study Coordinator
Phone: (844) 878-2446
Email: medicalinformation@taihooncology.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Cholangiocarcinoma
Explore by condition: All Advanced Cholangiocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.